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Abstract Necroptosis was initially identified as a backup
cell death program when apoptosis is blocked. However, it
is now recognized as a cellular defense mechanism against
infections and is presumed to be a detrimental factor in
several pathologies driven by cell death. Necroptosis is a
prototypic form of regulated necrosis that depends on
activation of the necrosome, which is a protein complex in
which receptor interacting protein kinase (RIPK) 3 is
activated. The RIP homotypic interaction motif (RHIM) is
the core domain that regulates activation of the necrosome.
To date, three RHIM-containing proteins have been
reported to activate the kinase activity of RIPK3 within the
necrosome: RIPK1, Toll/IL-1 receptor domain-containing
adaptor inducing IFN-b (TRIF), and DNA-dependent
activator of interferon regulatory factors (DAI). Here, we
review and discuss commonalities and differences of the
increasing number of activators of the necrosome. Since
the discovery that activation of mixed lineage kinase
domain-like (MLKL) by RIPK3 kinase activity is crucial in
necroptosis, interest has increased in monitoring and ther-
apeutically targeting their activation. The availability of
new phospho-specific antibodies, pharmacologic inhibitors,
and transgenic models will allow us to further document
the role of necroptosis in degenerative, inflammatory and
infectious diseases.
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Abbreviations
cIAP Cellular inhibitor of apoptosis protein
cFLIP Cellular FLICE-like inhibitory protein
CypD Cyclophilin D
CYLD Cylindromatosis
DAI DNA-dependent activator of interferon
regulatory factors
DR Death receptor
FADD Fas-associated protein via a death domain
FasL Fas
MLKL Mixed lineage kinase domain-like
Nec-1 Necrostatin-1
NLR NOD-like receptor
NLRP3 NOD-like receptor family pyrin domain-
containing protein 3
PAMP Pathogen-associated molecular patterns
PARP1 Poly(ADP-ribose) polymerase 1
RHIM RIP homotypic interaction motif
RIG-I Retinoic acid-inducible gene-I
RIPK Receptor-interacting protein kinase
ROS Reactive oxygen species
TAK1 Transforming growth factor-b-activated
kinase 1
TLR Toll-like receptor
TNFR Tumor necrosis factor receptor
TRADD TNFR-associated death domain protein
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TRAF2 TNFR-associated factor 2
TRAIL-R TNF-related apoptosis-inducing ligand
receptor
TRIF Toll-interleukin-1 receptor domain-
containing adaptor inducing interferon-b
TWEAKR TNF-like weak inducer of apoptosis receptor
VV Vaccinia virus
Introduction
Rudolf Virchow (1821–1902, Prussia), founder of the cell
theory (Omnis cellula e cellula) and cellular pathology,
referred to tissue injury as ‘‘parenchymatous inflamma-
tion’’ and introduced the idea that tissue injury is caused by
pathological changes within the cells. In 1858, he intro-
duced the notion of cell death as a potential basis for
pathology, with ‘necrobiosis’ being a physiological process
of spontaneous wearing out of living parts from the body
and ‘necrosis’ an accidental process. The term ‘necrosis’
comes from the Greek word ‘nekros,’ which means ‘dead
body.’ Virchow’s necrobiosis–necrosis dichotomy resem-
bles to some extent the current apoptosis–necrosis
classification [1]. Together with cellular and molecular
insights into inflammation came a shift in our under-
standing of the molecular interplay between cell death and
inflammation at the site of tissue injury. This emerging
field of research is crucial for understanding organismal
homeostasis and how its processes contribute to a growing
list of inflammatory and degenerative pathologies.
Although cell death during inflammation was initially
considered a manifestation of tissue damage, it was later
recognized as a mechanism for eliminating pathogens and
regulating inflammation by exposing or releasing molecu-
lar patterns that attract and alter the functions of other cells
[2]. More recently, it became clear that phagocytosis of
apoptotic cells can also initiate anti-inflammatory and tis-
sue-regenerative responses [3, 4].
The current notion that not only apoptotic but also
necrotic cell death is molecularly controlled by defined
signaling mechanisms has increased the interest in
studying regulated necrosis in the context of development,
homeostasis and inflammation. Although RIPK3 knockout
mice and MLKL knockout mice do not show an overt
phenotypic abnormality under non-challenged conditions
[5–8], it became clear that RIPK3-mediated necroptosis is
a highly controlled cell death program that is executed
when negative regulators such as caspase-8, IAPs or even
RIPK1 are absent [9–17]. This suggests that the default
mode during development and homeostasis is strong
inhibition of the necroptosis pathway. Regulated necrosis,
like passive necrosis due to physico-chemical insult, is
caused by loss of plasma membrane integrity leading to
cellular rounding followed by swelling (oncosis). When
the immune system recognizes cellular content exposed or
released due to loss of membrane integrity, it initiates an
inflammatory response. Regulated necrosis can be classi-
fied into several cell death modalities, such as necroptosis,
parthanatos, ferroptosis, cyclophilin D-dependent necrosis,
(n)etosis and pyroptosis [18]. Each type of regulated
necrosis has particular biochemical features, yet it is not
clear whether the common morphological features of
these forms of cell death share or converge on common
pathways. Other forms of cellular death are being iden-
tified, such as entosis [19], autosis [20, 21] and
autoschizis [22].
Necroptosis, the best-characterized form of regulated
necrosis, is mediated by the concerted action of receptor
interacting protein kinase (RIPK) 3 and mixed lineage
kinase domain-like (MLKL). In this review, we provide a
snapshot of the activation of RIPK3 within the necrosome,
typically by the three RHIM-containing proteins RIPK1,
Toll/IL-1 receptor domain-containing adaptor inducing
IFN-b (TRIF) and DNA-dependent activator of interferon
regulatory factors (DAI). We briefly discuss the pluripotent
roles of RIPK1 and RIPK3 in gene regulation and cell
death induction.
RIPK1-dependent necroptosis
The mechanism of RIPK1-dependent necroptosis has been
discovered mostly from studying tumor necrosis factor
(TNF) signaling under conditions favoring cell death. This
is because the major function of TNFR1, like that of DR3
(TRAMP/APO-3), is to induce pro-survival and pro-in-
flammatory genes, in contrast to some other death
receptor family members such as CD95 (FAS/APO-1),
TRAILR1 (DR4) and TRAILR2 (APO-2/TRICK/DR5/
KILLER). The following model is currently proposed for
TNFR1 signaling: sensing of trimeric TNF by TNFR1
induces the assembly of a primary receptor-bound com-
plex that triggers activation of signaling pathways leading
to gene induction [23–25]. Subsequently, assembly of a
secondary TNFR1-unbound cytosolic complex induces
cell death. For FAS and TRAILR1/2, the opposite situa-
tion is observed [26]. This sequential signaling provides a
backup response by the secondary cytosolic complex in
case the default pathway activated by the receptor-asso-
ciated complex fails to resolve the infectious or
inflammatory condition. Typically, pathogens and (epi)-
genetic factors can interfere with gene activation or cell
death induction. Thus, this sequential signaling probably
evolved as a host defense against pathogens or conditions
that might perturb either pathway.
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In this review, wewill briefly describe cell death signaling
downstream of TNFR1, with a focus on necrosome activa-
tion. A cytosolic cell death-inducing complex is formed
upon stimulation of TNFR1 only in conditions that sensitize
to cell death, for example when cellular inhibitor of apop-
tosis proteins (c-IAPs) are absent (IAP-antagonist
treatment), TAK1 or translation is inhibited, or RIPK1 is
deubiquitinated [18]. This cytosolic complex (often referred
to as complex II), which is composed of at least RIPK1, the
death-fold-containing proteins Fas-associated protein via
death domain (FADD), CASP8, and cFLIP (Fig. 1), induces
either apoptosis or necroptosis. The formation and/or
activity of complex II is tightly regulated by inhibitor jB
kinases (IKKs) through mechanisms that are either depen-
dent or independent of NF-jB [27].
Necroptosis is typically initiated when caspases are
insufficiently activated or their activity is blocked, for
example by pharmacological or viral inhibitors. This con-
cept was first proposed based on studies of DR signaling in
fibrosarcoma cells [28, 29], and later confirmed in vivo by
the rescue of the embryonal lethality of CASP8 or FADD
deficiency by RIPK3 depletion [9, 14, 16]. CASP8 cleaves
and inactivates RIPK1 [30], RIPK3 [31] and cylindro-
matosis (CYLD) [32]. This could at least partially explain
the protective role of CASP8 against necroptosis [33, 34].
It is thought that CYLD is crucial for translocation of
RIPK1 from receptor-bound complex I to the cytosolic
death-inducing complex II by removing ubiquitin chains
from RIPK1 [35, 36]. However, recently it became clear
that complex II is also ubiquitylated, although the E3
Fig. 1 Canonical versus noncanonical necrosome activation by three
distinct RHIM-containing host adaptors. RIPK1 is a key pro-necrotic
kinase that responds to several DRs, TCR, IFN-cR and genotoxic
stress by forming a RIPK1–RIPK3 complex through RHIM-depen-
dent interactions (referred to as canonical necrosome). Necrostatin-1s
(Nec-1s) blocks the cytotoxicity induced by the kinase activity of
RIPK1. In TNFR1 signaling, cell death is efficiently induced only
upon formation of a cytosolic cell death–inducing complex (complex
II) when, for example, cellular inhibitor of apoptosis proteins (c-IAPs)
are absent or depleted (IAP-antagonist treatment), TAK1 or transla-
tion is inhibited, or RIPK1 is deubiquitinated. In addition, caspases
need to be inactivated or depleted, for example by pharmacological or
viral inhibitors, to allow necroptosis to occur. TRIF and DAI are two
other RHIM-containing adaptors that can activate RIPK3 via RHIM-
dependent interactions in response to TLR3/-4 and MCMV,
respectively (referred to as noncanonical necrosomes). RIPK3, upon
activation by RIPK1, TRIF or DAI, phosphorylates itself and
subsequently MLKL to stimulate oligomerization and translocation
of MLKL to intracellular and plasma membranes. It is assumed that
MLKL induces membrane rupture by binding directly to membrane
phospholipids or indirectly with the help of calcium or sodium ion
channels. Necrosulfonamide targets human MLKL and blocks
necroptosis induction. DAI DNA-dependent activator of interferon
regulatory factors, DR death receptor, FADD Fas-associated protein
via a death domain, IFN interferon, MCMV murine cytomegalovirus,
MLKL mixed lineage kinase domain-like, NSA necrosulfonamide,
LPS lipopolysaccharide, RIPK receptor-interacting protein kinase,
TCR T cell receptor, TLR Toll like receptor, TNF tumor necrosis
factor, TRIF Toll-interleukin-1 receptor domain-containing adaptor
inducing interferon-b
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ligases have not been identified yet [37–41]. While com-
plex II is formed through interactions that depend on the
death effector domain (DED) and the death domain (DD),
RIPK1 and RIPK3 interact through RIP homotypic inter-
action motifs (RHIM) [6, 42–45]. It is assumed that this
RHIM-dependent binding of RIPK1 and RIPK3 involves a
conformational change that releases the RHIM domain
[46]; the conformational change depends on posttransla-
tional modifications, particularly the phosphorylation and
ubiquitination status. A series of auto- and cross-phos-
phorylations between RIPK1 and RIPK3 result in the
formation and activation of the canonical necrosome [43,
47], which appears as an amyloid-like structure of RHIM-
dependent oligomerized RIPK3 [48]. The phosphorylation
of human RIPK3 at Ser227 and mouse RIPK3 at Ser232 is
crucial for recruitment of mixed lineage kinase domain-like
(MLKL) [49–52]. Subsequent phosphorylation of MLKL at
Thr357/Ser358 by human RIPK3 [50] or at Ser345/Ser347/
Ser352/Thr349 by mouse RIPK3 [52] stimulates its
oligomerization and translocation to intracellular and
plasma membranes. The precise mechanism by which
MLKL induces membrane rupture is controversial. Some
reports implicate the influx of calcium or sodium through
ion channels [53, 54] whereas others show direct binding to
membrane phosphatidylinositol phosphates and loss of
membrane integrity [55, 56].
In addition to TNF receptor signaling, other receptors
induce necroptosis through RIPK1-dependent necrosome
activation (Fig. 1; Table 1). These receptors include
CD95L (FasL/APO-1L) [57], TRAIL (TNF-related apop-
tosis-inducing ligand or Apo2L) [57], TWEAK (TNF-like
weak inducer of apoptosis) [58], and T cell receptor (TCR)
[59]. Also, genotoxic stress [60, 61] and some anti-cancer
drugs such as shikonin [62, 63] and obatoclax [64] have
been shown to induce RIPK1-dependent necroptosis
(Table 2). However, the assumption that many
Table 1 Overview of experimental findings of ligand-induced necroptosis involving MLKL
Trigger Major finding References
TNF Discovery of MLKL downstream of RIPK3 [50, 125]
Quantitative phosphoproteomic analysis of RIP3-dependent protein phosphorylation [126, 127]
Trimerized MLKL acts at plasma membrane to allow Ca2? influxvia TRPM7 [53]
MLKL unleashes four-helical bundle to induce membrane rupture
Discovery of mouse MLKL targeting compound 1
[128]
Depletion of RIPK3 or MLKL favors RIPK1 kinase-dependent apoptosis [92]
RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis [129]
Hsp90 and Cdc37 are required for RIPK3 activation [130]
Necroptosis is preceded by nuclear translocation of RIPK1, RIPK 3 and MLKL [131]
Radical scavengers attenuate necrosome assembly [132]
Ponatinib and pazopanib inhibit necroptosis by targeting RIPK1 [133]
Structure-guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1 [134]
Clnk promotes necroptosis downstream of RIPK3 and upstream of MLKL [135]
Intracellular NAD? promotes TNF-induced necroptosis in a sirtuin-dependent manner [136]
TRAF2 suppresses necrosome assembly [117]
MLKL and cofilin-1 translocation to mitochondria, Bax/Bak oligomerization, CypD and downregulation of
Mcl-1 contribute to necroptosis
[137]
Ser345 is crucial for MLKL translocation and subsequent necroptosis [138]
LPS RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL [139]
MLKL and PGAM5 upstream of NLRP3-mediated IL-1b maturation in caspase-8-deficient dendritic cells [94]
TLR1/2,3,4,7/8 ligands Caspase blockade induces RIP3-mediated programmed necrosis in Toll-like receptor-activated microglia [140]
polyIC/ATP Caspase-8 scaffolding function and MLKL regulate NLRP3 inflammasome activation downstream of
TLR3
[141]
a-GalCer Regulation of NKT cell-mediated immune responses to tumors and liver inflammation by mitochondrial
PGAM5-Drp1 signaling
[142]
RIPK3 dimerization Necroptosis is dependent on MLKL but not on DRP1 [143]
MLKL dimerization MLKL compromises membrane integrity by binding to phosphatidylinositol phosphates [55]
RIPK1 and -3
oligomerization
RIPK3 homo-oligomerization results in amyloid scaffold, RIPK3 autophosphorylation and MLKL docking [144–146]
CD40L CD40L induces necrosome-dependent necroptosis in low-grade serous carcinomas [147]
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chemotherapeutics induce RIPK1/3-mediated necroptosis
was recently challenged [65].
TRIF-dependent necroptosis
RIPK1 is the central RHIM-containing protein involved in
the activation of RIPK3 during TNF-induced necroptosis,
which leads to the formation of the so-called canonical
necrosome complex. However, in response to some Toll-
like receptors (TLRs), the RHIM-containing protein TRIF
somehow activates RIPK3 independently of RIPK1 [44,
45], leading to assembly of the noncanonical necrosome
complex [46]. Each member of the TLR family senses
particular pathogen-associated molecular patterns [66].
When activated, TLRs recruit adaptors containing the Toll/
IL-1R (TIR) domain and initiate NF-jB and IRF3/7 sig-
naling that trigger the expression of cytokines, chemokines
and interferons. All TLRs, with the exception of TLR3 and
TLR4, mediate the signal through the adaptor myeloid
differentiation primary-response gene 88 (MYD88). On the
other hand, TLR3 and TLR4, after binding of the ligand
Table 2 Overview of experimental findings of chemical-, toxin- or virus-induced necroptosis involving MLKL
Trigger Major finding References
BV6/MS275/
zVADfmk
Combination of SMAC-mimetics, HDAC inhibitors and caspase inhibition induces RIPK1- and MLKL-
dependent necroptosis
[148]
NPe6-PDT Photodynamic therapy using a high dose of the photosensitizer talaporfin sodium induces RIPK1, RIPK3
and MLKL-dependent necroptosis
[149]
CCCP Impaired oxidative phosphorylation regulates MLKL-dependent necroptosis [150]
Cigarette smoke
extract
Nex-5 and Nec-1 protect against cell death induced by cigarette smoke extract [151]
Shikonin RIPK1- and RIPK3-dependent necroptosis [152]
Obatoclax Necrosome formation at autophagosomal membranes [64]
Staurosporine/
zVADfmk
NSA blocks S/Z-induced necroptosis [153]
Cytarabine/SMAC-
mimetic
Nec-1 or NSA block TNF-mediated necroptosis [154]
Thapsigargin
tunicamycin
RIPK1/RIPK3/MLKL-mediated necroptosis in mouse fibrosarcoma cells [155]
Edelfosine RIPK1/RIPK3/MLKL-mediated necroptosis in human glioblastoma cells [156]
Cisplatin RIPK1-dependent necroptosis in squamous cell carcinoma [157]
Doxorubicine
etoposide
RIPK3-/MLKL-dependent cell death [158]
Homoharringtonine Sensitizes TRAIL-induced necroptosis [159]
Acetylcholinesterase-R
peptide
RIPK1/MLKL-mediated necroptosis in human granulosa cells [160]
PMA Neutrophil extracellular trap formation can involve RIPK1-RIPK3-MLKL signaling [161]
NET formation can occur independently of RIPK3 and MLKL signaling [162]
CNOT3-deficiency CNOT3 suppression promotes necroptosis by stabilizing mRNAs for cell death-inducing proteins [163]
Neoalbaconol Neoalbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNF [164]
Chal-24 A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer
chemotherapy
[165]
Hypoxia Glycolytic pyruvate scavenging of mitochondrial superoxide protects against necroptosis [166]
Honokiol Honokiol induces RIPK3- and CypD-mediated necroptosis [167]
RNA viruses RIPK1/RIPK3/DRP1-mediated NLRP3 activation [168]
CMV DAI complexes with RIPK3 to mediate virus-induced programmed necrosis [74]
Human CMV blocks TNF-induced necroptosis downstream of RIPK3 and MLKL [169]
HSV-1 Mouse ICP6 triggers RIPK3/MLKL-dependent necroptosis [170]
Staphylococcus aureus
toxin
SA toxin triggers RIPK1/RIPK3/MLKL-dependent necroptosis [107]
HSV-1 and -2 Human, but not mouse, HSV-1 and -2 prevent necrosome-dependent necroptosis [171–173]
HIV HIV-1 protease cleaves RIPK1 and RIPK2 [174]
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(dsRNA and LPS, respectively), recruit the RHIM domain
containing adaptor TRIF [67]. Both TLR3 and TLR4
directly induce apoptosis or, if caspase activity is com-
promised, necroptosis [42, 68, 69]. Several other TLRs,
such as TLR2, TLR5 and TLR9, also induce cell death but
through an endocrine or paracrine TNF-dependent mech-
anism [70]. TLR3/4-induced necroptosis is critically
dependent on RHIM-mediated recruitment of TRIF to
activate RIPK3 (Fig. 1) [69, 70]. Like RIPK1 and RIPK3,
TRIF is a cleavage substrate of CASP8 that inhibits its
ability to stimulate NF-jB-dependent cytokine expression
[71]. Notably, RIPK1 seems to have a cell type specific
function in TLR3/4-induced cell death. While fibroblast
and endothelial cells undergo TLR3-dependent necroptosis
independently of RIPK1, macrophages require RIPK1 to
commit to TLR3/4-mediated necroptosis [70].
DAI-dependent necroptosis
In addition to RIPK1 and TRIF, a third RHIM-containing
protein, DAI, has been reported to activate the necrosome
(Fig. 1). The DAI pathway is typically activated in response
to DNA viruses and leads to inhibition of viral replication
[72]. Like TLR signaling, the intracellular DNA sensor
activates the NF-jB and IRF3 pathways to promote the
synthesis of cytokines and interferons,which is dependent on
RHIM-mediated recruitment of RIPK1 [73]. In addition, in
response to DNA viruses, DAI induces necroptosis through
RHIM-mediated activation of RIPK3 in the noncanonical
necrosome [74]. As a virus-encoded countermeasure, the
murine cytomegalovirus (CMV) M45-encoded viral inhi-
bitor of RIP activation (vIRA) acts as a RHIM competitor
and blocks necroptosis, which explains the virus’s successful
replication in the host. The potency of this cell autonomous
host defense pathway is demonstrated by the remarkable
attenuation ofM45-deficient viruses inmice. Importantly, as
in RIPK3-deficient mice, mCMV lacking M45 has the same
pathogenesis in DAI-deficient mice, consistent with the
notion of the existence of a DAI–RIPK3 complex as the
natural target of M45 [74]. M45 encodes a ribonucleotide
reductase (RNR) lacking enzymatic activity. Interestingly,
many RNRs from herpesviruses also encode a RHIM [75].
This suggests that viral inhibitors that target the RIPKs via
the RHIM represent a common viral evasion strategy.
The Janus faces of RIPK1
The ‘two faces’ of RIPK1 refers to its dual role. It has a cell
death inhibitory role that is shown by the massive cell death
observed in RIPK1-deficient models, whereas its
necroptosis-inducing capacity is executed by its kinase
activity. In the absence of RIPK1, massive apoptosis is
observed in cells [34, 76], in postnatal death knockout mice
[77], and in intestinal specific knockout mice [12, 13]. It was
initially thought that this was due to the role of RIPK1 in
mediating NF-jB activation, which results in the expression
of survival genes such as FlipL [77]. In this respect, cFLIPL-
CASP8 heterodimers have partial enzymatic activity, lead-
ing to incomplete cleavage of CASP8 [78, 79], and this
consequently prevents apoptosis. Nevertheless, it is thought
that CASP8 has some local activity within complex II
resulting in cleavage of RIPKs and CYLD [80], which may
contribute to the anti-necroptotic role of CASP8. However,
mounting evidence questions the necessity or uniqueness of
the role of NF-jB activation in controlling cell death. For
example, NF-jB is still activated in response to TNF stim-
ulation in the absence of RIPK1 in cultured MEF cells [81]
and in intestinal organoids [13]. TAB2-deficient mice have a
functional NF-jB pathway, yet they die from massive liver
apoptosis like mice deficient in p65, IKKb, TAK1 or NEMO
[82]. Moreover, the rescue of mutant RIPK1 kinase-dead
knockin mice from TNF-induced shock [10, 11, 83, 84] and
from the lethal TNF-induced inflammation in Sharpin
mutant mice [83] also calls into question the dominance of
NF-jB activation (that occurs in a RIPK1 kinase indepen-
dent way). This is underscored by the recent finding that
IKKa and IKKb control RIPK1-mediated cell death inde-
pendently of NF-jB activation [27].
The dual role of RIPK1 in controlling cell death is also
illustrated by the perinatal death of RIPK1 knockout mice
due to the aberrant activation of caspase-8 and RIPK3;
mice lacking all three enzymes survived to adulthood [10,
14, 85]. Indeed, in addition to its anti-apoptotic role,
RIPK1 also prevents RIPK3-driven necroptosis promoted
by IFN and the TLR-adapter TRIF [14]. Since RIPK1 is
reported to be essential for RIPK3 activation and subse-
quent necroptosis induction by TNF, the identification of
settings in which RIPK1 actively suppresses RIPK3 was
surprising. Moreover, conditional depletion of RIPK1 leads
to apoptosis in the intestine and necroptosis in the skin [12,
13]. This dynamic interplay and interdependence of these
complex II components confers a crucial host-defense
function to limit pathogen spread, especially when any one
of these processes is disrupted [72, 86]. This may explain
why this complex interrelationship exists and why ablation
of specific elements (including RIPK1, FADD, caspase-8
and cFLIP) push the system to lethality [87]. In line with
this reasoning, the tissues most affected by disruption of
these gene products (intestine, lung, skin, endothelium,
hematopoietic cells) represent crucial barriers to infection
that are constantly engaged by pathogens [88]. Depending
on the tissue, cell type and developmental stage, RIPK1
can certainly either activate or inhibit cell death.
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The pleiotropic role of RIPK3
Whereas RIPK3 knockout mice are viable and fertile [5,
89], RIPK3 D161N kinase dead knockin mice die on
embryonic day E10.5 due to massive levels of apoptosis in
the embryo and yolk sac vasculature [11]. But this was not
observed in RIPK3 D51A kinase dead knockin mice
Mandal et al. [89]. The embryonic death of RIPK3 D161N
kinase dead knockin mice was rescued by ablation of
RIPK1 or caspase-8, indicating that RIPK3 can engage
both RIPK1 and caspase-8 [11]. It remains unclear
structurally why the D161N kinase-dead mutation in
RIPK3 is proapoptotic, though it is likely that the kinase
domain functionally ‘‘masks’’ the RHIM domain to prevent
spurious activation [90]. In this scenario, the D161N alters
the conformation of RIPK3 so that the RHIM domain is
exposed for binding to RIPK1 to initiate apoptosis. This
model predicts that the kinase and RHIM domains col-
laborate to control scaffolding of the necroptotic and
apoptotic machineries. Some RIPK3 inhibitors were also
found to induce apoptosis in a similar way through RHIM-
dependent RIPK1 docking and subsequent FADD/CASP8-
Table 3 Overview of genetic necroptosis studies in experimental mouse pathologies
Genetic defect Major finding References
RIPK3KO Protects against pancreatitis [6, 42]
Sensitizes to vaccinia virus infection [43]
Protects against photoreceptor loss (?Nec-1) [102]
Protects against TNF-induced SIRS [103]
Partially protects from macrophage death and enhances bacterial control upon Salmonella infection [104]
Rescues the mid-gestation defect of cIap2/1-deficient embryos [105]
Protects against intracerebroventricular injection of TNF in mouse hippocampus [106]
Improves clearance of Staphylococcus aureus (?Nec-1s) [107]
Diminishes cutaneous wound healing [108]
Protects against ethanol-induced liver injury [109]
Protects from macrophage necroptosis in atherosclerosis development [110, 111]
Rescues mild systemic inflammatory disease in macrophage-specific CASP8 knockouts [112]
Protects against cone cell necrosis in a mouse model of inherited degeneration [113]
Protects against dsRNA-induced retinal degeneration [114]
Protects against myocardial infarction [115]
Protects against non-alcoholic steatohepatitis [116]
Partial rescue of TRAF-2-deficient mice [117]
Protects against Gaucher’s disease [118]
Protects against Ppm1b-mediated sensitization to TNF-induced SIRS [119]
Protects RIPK1E-KO from skin inflammation [12]
MLKLKO Deficiency of RIPK3 or MLKL does not protect against shock induced by cecal ligation and puncture
MLKL deficiency protects against pancreatitis
[7]
Nec-1 treatment and RIPK3 or MLKL deficiency protect against cisplatin-induced acute kidney injury [120]
Acetaminophen-induced liver toxicity occurs through RIPK1 but independently of RIPK3 and MLKL [121, 122]
No difference in diabetes onset by RIPK3- or MLKL-deficiency [123]
RIPK3 or MLKL deficiency partially protects from inflammation induced by sharpin deficiency [124]
RIPK1IEC-KO RIPK1 protects the intestinal epithelium against apoptosis [12, 13]
RIPK1E-KO RIPK1 partially protects the skin from necroptosis [12]
RIPK3K51A Viable and fertile [89]
RIPK3D161N Embryonic lethality rescued by Casp8-deficiency [11]
RIPK1K45A Protect Sharpin-deficient mice from inflammation [83]
RIPK1D138N Protects against TNF-induced shock [11, 84]
Does not protect against necroptosis of FADD-deficient IEC cells [12]
RIPK1/3/CASP8KO Rescue Ripk1-/- neonatal lethality by Ripk3 and Casp8 depletion [14, 85]
[10]
RIPK3/CypDKO Protects against renal ischemia reperfusion injury [100]
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mediated apoptosis [70, 89]. Note that RIPK3 has also been
reported to positively contribute to RIPK1-dependent
apoptosis independently of its kinase activity but remark-
ably also of its RHIM domain [37]. While TNF signaling
typically requires RIPK1 to activate RIPK3 in order to
induce necroptosis, it has been noted that TNF can trigger
RIPK3 activation even in the absence of RIPK1 if RIPK3
levels are high enough [91]. In the absence of RIPK1 and
the presence of elevated levels of RIPK3, TNF can activate
RIPK3 to induce cell death by both a caspase-8-dependent
mechanism and a caspase-independent mechanism [37,
91]. Finally, similar to depletion of RIPK1 [34, 76],
blocking TNF-induced necroptosis by suppressing RIPK3
or MLKL toggles the cell death response to apoptosis,
albeit with different kinetics [92]. Collectively, these
studies indicate that precise control of the complex II
machinery is necessary to prevent a lethal imbalance of
necroptotic or apoptotic pathways.
Concluding remarks
There has been a revival of interest in the close intercon-
nection between cell death and inflammation originally
recognized by Virchow. This interconnection is empha-
sized by some recent findings that classical cell death
inducers such as caspase-8 and RIPK3 seem to act also
upstream of inflammasome activation in a cell autonomous
way [93–98]. However, the precise mechanisms of this
interaction are unclear. RIPK1 as well as RIPK3 and other
cytosolic TNFR complex II components have been impli-
cated in regulating cell death and inflammation, though if
Table 4 Overview of pharmacologic targeting of necroptosis in experimental rodent pathologies
Pharmacologic agent Major finding References
Nec-1 Alleviates ischemic brain injury [47]
Is cardioprotective [175]
Improves outcome after controlled cortical impact [176]
Alleviates retinal ischemia reperfusion injury [177]
Alleviates spinal cord injury pathology in rats [178]
Alleviates injury in subtotal nephrectomised rats [179]
Nec-1s Nec-1s treatment reduces disease severity in experimental autoimmune encephalitis model [180]
NSA Nec-1 or NSA block death in models of both sporadic and familial ALS (ex vivo) [181]
Dabrafenib Targets RIPK3 and alleviates acetaminophen-induced liver injury [182]
Upregulated RIPK3 expression potentiates MLKL phosphorylation-mediated programmed necrosis in
toxic epidermal necrolysis
[183]
Nec-1, SanglifehrinA,
16-86
Protects from renal ischemia reperfusion injury [99]
Nec-1, cyclosporine A,
3-AB
Protects from remote lung injury after receiving ischemic renal allografts in rats [101]
Table 5 Overview of studies linking necroptosis to human pathologies
Disease Major finding References
Ovarian cancer Low MLKL expression associated with poor prognosis [184]
Inflammatory bowel disease High RIPK3 and MLKL expression [185]
Drug-induced liver injury Phosphorylated MLKL in biopsies [56]
Chronic obstructive
pulmonary disease
Increased levels of RIPK3 in lung epithelial cells [151]
Multiple sclerosis Increased levels of RIPK1, RIPK3 and necrosome formation in lesions [180]
Breast cancer Weak RIPK3 expression [158]
Melanoma Melanoma cell lines lack RIPK3 expression, whereas primary melanocytes strongly express RIPK3 [186]
HIV Dysfunctional HIV-specific CD8? T cell proliferation is associated with increased caspase-8
activity and mediated by necroptosis
[187]
Leukemia RIPK3 is downregulated [188]
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these functions could be uncoupled is not clear. In addition,
the potential signal transduction interplay between
parenchymal cell necrosis and some forms of necrosis that
occur in immune cells, such as pyroptosis and netosis,
remains unknown. Considering the central role of RHIM
domains in controlling the cell death induced by several
stimuli, small molecules that disrupt RHIM signaling might
also be therapeutically useful.
The number of genetic (Table 3) and pharmacological
studies (Table 4) demonstrating an important role for
RIPK1, RIPK3 or MLKL in murine experimental disease
models is still increasing, highlighting the therapeutic
potential of these necrosome members. In addition, the
expression and activation of RIPK1, RIPK3 and MLKL is
being increasingly explored in biopsies of patients with
particular pathologies driven by cell death and inflamma-
tion (Table 5). The availability of new phospho-specific
antibodies, pharmacologic inhibitors and transgenic models
will allow us to document further the role of necroptosis in
degenerative, inflammatory and infectious diseases. It is
noteworthy that therapeutic targeting of only necroptosis
might be insufficient in some complex pathologies, as
exemplified by the additive protective effect of targeting
different types of regulated necrosis [99–101]. This
observed redundancy of necrosome proteins and interplay
between different modalities of necrotic cell death in vivo
is an intriguing topic for further research and will generate
further insight into how the targeting of these molecules in
some cases looks very effective.
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